[ad_1]
The Oxford-AstraZeneca-Irbm Covid vaccine, which will be marketed and distributed after the necessary regulatory approvals, is 90% effective based on interim data released today by the same manufacturer. In fact, they were tested in the phase 3 trial. two different administration regimens. The regimen proved to be the best, with an efficacy of only 90% and maximum tolerability for the elderly., is the one that involves the inoculation of half a dose and a booster with a full dose per month. This is the vaccine regimen that will be considered for marketing.
The second regimen was 62% effective and would have provided for two full doses one month apart. There was also one Combined analysis of the two regimens, which gave a mean vaccine efficacy of 70%. After the results of Modern me Pfizer (with an efficiency greater than 90%), which used the innovative messenger RNA technique, those of the British university were disseminated whose vaccine consists of a harmless viral vector (chimpanzee adenovirus) that has been modified with a spike protein graft surface of coronavirus.
These are the preliminary results of the experimentation launched on a large scale and in various countries around the world. In any case, in the trial participants, ongoing in Great Britain and Brazil, there was no hospitalization or serious case of COVID-19. The cost of € 2.80 per full dose has been confirmed. The company will submit data to global regulatory authorities for conditional or early approval and will also apply for emergency use to the World Health Organization to accelerate the path to vaccine availability in low-income countries. Full analysis of intermediate results was submitted for publication in a scientific journal.
Astrazeneca: “No serious events have been confirmed” – All the results turned out to be “Statistically significant“Astrazeneca stresses, specifying that the independent data security monitoring commission has determined that the analysis has reached its final point primary showing protection against Covid-19. “No serious events have been confirmed,” continues the multinational. “AZD1222 was well tolerated in both dosing regimens.” Further United Kingdom me Brazil, Astrazeneca is also conducting clinical trials in United States, Japan, Russia, South Africa, Kenya me America Latina with studies planned in other European and Asian countries. In total, the company plans to enroll up to 60,000 attendees globally.
The strength of the vaccine developed in the Oxford laboratories is that it definitely turns out cheaper than the other two, as well as easier to store and therefore it can be available anywhere in the world. For this reason, if approved, “it could play an important role in the fight against the pandemic.” The British government has already ordered 100 million doses of the vaccine developed by the University of Oxford. enough to immunize 50 million people. “Today marks an important step in our fight against the pandemic. The efficacy and safety of this vaccine confirm that it will be highly effective against Covid-19 and will have an immediate impact on this health emergency, says Pascal Soriot, CEO of AstraZeneca. The simple vaccine supply chain and our nonprofit commitment to broad, fair and timely access means it will be affordable and available globally, providing hundreds of millions of doses. “The company also says it has the capacity to make more than 3 billion available of AZD1222 doses in 2021, pending approval. The vaccine, the company notes, can be stored, transported and handled under normal refrigeration conditions (2-8 degrees Celsius) for at least 6 months and managed within existing healthcare facilities.
Oxford Scientists: “Exciting Result” – The Oxford researchers, who went through the normal ten-year process to develop a vaccine in about ten months, noted that there is data to suggest that refining the dose could increase protection by up to 90%. “Today’s announcement takes us one step closer to when we can use vaccines to end the devastation caused by the virus,” he said. Sarah Gilbert of the Oxford University. More than 20,000 volunteers participated in the trial, half in the UK and half in Brazil. There have been 30 cases of Covid in people who received two doses of the vaccine and 101 cases in people who received a sham injection. There are four million ready-to-use doses in the UK, with another 96 million to be delivered. To do this, we will have to wait for the approval of the regulatory authorities that will evaluate the safety, efficacy and production of the vaccine.
The result “is exhilarating” and means that the product “could save many human lives,” says Professor Andrew Pollard, director of trials on behalf of the University of Oxford. “It’s exciting – explained Pollard on the sidelines of today’s announcement – that we have verified how in one of our doses (the single dose, ed) results can be effective in approximately 90% of cases: If this dosage is used, among other things, a greater number of people can be vaccinated with the supplies provided “at this time.” Today’s announcement has been possible only by volunteers who have undergone our experimentation and to the teams of talented researchers who have worked with us around the world ”, continued the academic, recalling that so far the trials have been carried out on 23,000 adults and that now it is expected to reach 60,000.
[ad_2]
